Key Takeaways KMTS announced a collaboration with Biobeat, including an exclusive license and a $5M Series B investment.KMTS integrates FDA-cleared cuffless blood pressure monitoring into the ASSURE WCD for at-home recovery.Per Kestra, ACE-PAS data reflects 72% hypertensive patients, highlighting BP challenges post-cardiac events.Kestra Medical Technologies, Ltd.(KMTS) announced a collaboration with Biobeat Technologies, Ltd. to improve patient monitoring and diagnosis insights for people who rely on the AS ...

Core Insights - Kestra Medical Technologies announced positive primary results from the ASSURE® WCD Clinical Evaluation Post-Approval Study (ACE-PAS), confirming the safety and effectiveness of the ASSURE WCD in clinical practice [1][2][3] Study Overview - ACE-PAS is the largest prospective real-world study of wearable defibrillators, enrolling 21,612 patients across the U.S. from November 2021 to July 2025 [6] - The study provides contemporary data on the risk of life-threatening ventricular tachycardia and fibrillation in patients with reduced cardiac function [2] Effectiveness and Safety - The primary effectiveness endpoint was achieved with a 100% successful conversion rate for ventricular tachycardia and fibrillation events, exceeding the prespecified performance goal [5] - The study met its primary safety endpoint, reporting an inappropriate-shock rate of 0.0065 per patient-month, confirming a strong safety profile [5] - 94% of patients experienced no false positive shock alarms, enhancing user confidence [5] Patient Protection and Compliance - 2.6% of patients experienced at least one life-threatening VT/VF event within a few months, underscoring the importance of the ASSURE WCD for vulnerable populations [5] - The device detected high-rate atrial fibrillation in 4.2% of patients, with 35% previously undiagnosed, and severe bradycardia/asystole in 0.3%, allowing for timely intervention [5] - Patients wore the device for a median of over 23 hours per day, with one-third continuing use beyond 90 days, indicating high compliance in real-world settings [5] Implications for Clinical Practice - The results of ACE-PAS may inform future updates to clinical practice regarding the identification and protection of patients at early risk of sudden cardiac death [3] - The study emphasizes the critical role of wearable device monitoring and therapy in managing sudden cardiac arrest risk [3]

KIRKLAND, Wash., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Kestra Medical Technologies, Ltd. (Nasdaq: KMTS), a wearable medical device and digital healthcare company, today announced its participation in the American Heart Association (AHA) Scientific Sessions 2025, to be held November 7–10 in New Orleans. Kestra’s participation will include a late-breaking science presentation titled Primary Results from the Post-Approval Study of a Next Generation Wearable Cardioverter Defibrillator System (ACE-PAS Trial), schedu ...

Core Insights - Kestra Medical Technologies, Ltd. is debuting its Cardiac Recovery System (CRS) platform at the 2025 Heart Failure Society of America Annual Scientific Meeting, highlighting its commitment to advancing care for heart failure patients [1][4]. Company Overview - Kestra Medical Technologies is a commercial-stage wearable medical device and digital healthcare company focused on improving patient outcomes in cardiovascular disease through intuitive, intelligent, and connected monitoring and therapeutic intervention technologies [5]. Product Features - The CRS platform includes the ASSURE Wearable Cardioverter Defibrillator, which aims to close the gap in sudden cardiac death protection by providing actionable insights during the early phase of heart failure recovery [2]. - Attendees at the conference can engage with the CRS platform through immersive experiences and hands-on demonstrations, showcasing its ability to empower clinicians and enhance patient-provider connections [3]. Industry Engagement - Kestra will also participate in the Devices in Heart Failure Meeting, allowing attendees to see the ASSURE system and understand its integration into clinical workflows to support guideline-directed medical therapy [4].